Thar Pharmaceuticals, Inc.

Grunenthal Gmbh

Thar Pharma, LLC

Hikma Pharmaceuticals USA Inc.

Insys Development Company, Inc.

Aclipse One, Inc.

Ning Shan

Miranda L Cheney

David R Weyna

Mazen Hanna

Raymond K Houck

Ningxin Yan

Paul Isbester

Mazen H Hanna

Rajesh Wakaskar

Xufeng Sun

Min Wu

Andrew B Schlinkert

Edwin A Baldwin

Miranda Cheney

David Weyna

The invention is directed to a novel crystalline S-apomorphine hydrochloride hydrate salt.

Crystalline form of s-apomorphine

Sublingual formulations containing an opioid, preferably, fentanyl or a pharmaceutically acceptable salt or ester thereof, naloxone or a pharmaceutically acceptable salt or ester thereof, and a terpene; as well as methods of treating pain by administering the formulations of the invention to a patient in need thereof.

Sublingual opioid formulations containing naloxone

The invention relates to the preparation and characterization of novel forms of (1-hydroxy-2-imidazol-1-yl-1-phosphono-ethyl) phosphonic acid. The invention also relates to the use of the novel forms of (1-hydroxy-2-imidazol-1-yl-1-phosphono-ethyl) phosphonic acid in pharmaceutical compositions in drug delivery systems for humans. The invention further relates to the use of the novel forms of (1-hydroxy-2-imidazol-1-yl-1-phosphono-ethyl) phosphonic acid or the pharmaceutical compositions thereof to treat and/or prevent a disease state associated with osteoporosis, tumor induced hypercalcemia (TIH), cancer-induced bone metastasis, Paget's disease or for adjuvant or neoadjuvant therapies.

Crystalline forms

Preparation and characterization of novel forms of (1-hydroxy-2-imidazol-1-yl-1-phosphono-ethyl) phosphonic acid, suitable for pharmaceutical compositions in drug delivery systems for humans.

Preparation, in-vitro and in vivo characterization of novel forms of (1-hydroxy-2-imidazol-1-yl-1-phosphono-ethyl) phosphonic acid, suitable for pharmaceutical compositions in drug delivery systems for humans.

Crystallization method and bioavailability

Preparation and in vitro and in vivo characterization of novel forms of active pharmaceutical ingredients, suitable for pharmaceutical compositions in drug delivery systems for humans.

Novel solution complexes of zoledronic acid are described which give rise to improved properties of zoledronic acid. The invention includes aqueous solution and molecular complexes of zoledronic acid with and optical isomers of asparagine, histidine, arginine and proline as well as pharmaceutical complexes containing them and methods of treatment using them.

Oral forms of a phosphonic acid derivative

Preparation, in-vitro and in vivo characterization of novel forms of (1-hydroxy-2-imidazol-1-yl-1-phosphono-ethyl)phosphonic acid, suitable for pharmaceutical compositions in drug delivery systems for humans.

Crystalline molecular complexes of tadalafil are disclosed. The crystalline molecular complexes include those of tadalafil and oxalic acid, tadalafil and 4-hydroxybenzoic acid, tadalafil and 3-phenylpropanoic acid, tadalafil and malonic acid, tadalafil and methylparaben, and tadalafil and propylparaben. Pharmaceutical compositions containing the crystalline molecular complexes are also disclosed.

Crystalline molecular comlpexes of tadalafil

The invention relates to novel crystalline forms of tadalafil suitable for pharmaceutical compositions in drug delivery systems for humans. More particularly, the invention relates to crystalline molecular complexes of tadalafil and methylparaben.

Growing community of inventors

Tampa, FL, United States of America

Ning Shan